These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33486885)

  • 41. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
    PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action.
    Facente SN; Grinstein R; Broussard J; Shost J; Azari S; Siruno J; Jimenez JA; Luetkemeyer AF; Burk K
    Public Health Rep; 2022; 137(4):649-654. PubMed ID: 35403488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polaris Observatory-supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis.
    Razavi H
    Antivir Ther; 2022 Apr; 27(2):13596535221083179. PubMed ID: 35499176
    [No Abstract]   [Full Text] [Related]  

  • 44. Hepatitis C elimination among people who inject drugs in Mexico during the COVID-19 pandemic.
    Márquez LK; Borquez A; Fleiz C; Magis-Rodríguez C; Rangel G; Strathdee SA; Martin NK
    Gac Med Mex; 2022; 158(2):110-113. PubMed ID: 35763823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis.
    Lim AG; Walker JG; Mafirakureva N; Khalid GG; Qureshi H; Mahmood H; Trickey A; Fraser H; Aslam K; Falq G; Fortas C; Zahid H; Naveed A; Auat R; Saeed Q; Davies CF; Mukandavire C; Glass N; Maman D; Martin NK; Hickman M; May MT; Hamid S; Loarec A; Averhoff F; Vickerman P
    Lancet Glob Health; 2020 Mar; 8(3):e440-e450. PubMed ID: 32087176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
    Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
    J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030.
    van Dijk M; Brakenhoff SM; Isfordink CJ; Cheng WH; Blokzijl H; Boland G; Dofferhoff ASM; van Hoek B; van Nieuwkoop C; Sonneveld MJ; van der Valk M; Drenth JPH; de Knegt RJ
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
    Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
    World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    Palayew A; Stumo SR; Cooke GS; Hutchinson SJ; Jauffret-Roustide M; Maticic M; Harris M; Metwally AM; Razavi H; Lazarus JV;
    PLoS One; 2020; 15(7):e0235715. PubMed ID: 32722701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Global hepatitis C elimination: an investment framework.
    Pedrana A; Howell J; Scott N; Schroeder S; Kuschel C; Lazarus JV; Atun R; Baptista-Leite R; 't Hoen E; Hutchinson SJ; Aufegger L; Peck R; Sohn AH; Swan T; Thursz M; Lesi O; Sharma M; Thwaites J; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):927-939. PubMed ID: 32730786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is global elimination of HCV realistic?
    Calvaruso V; Petta S; Craxì A
    Liver Int; 2018 Feb; 38 Suppl 1():40-46. PubMed ID: 29427499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination.
    Hagan LM; Kasradze A; Salyer SJ; Gamkrelidze A; Alkhazashvili M; Chanturia G; Chitadze N; Sukhiashvili R; Shakhnazarova M; Russell S; Blanton C; Kuchukhidze G; Baliashvili D; Hariri S; Ko S; Imnadze P; Drobeniuc J; Morgan J; Averhoff F
    BMC Public Health; 2019 May; 19(Suppl 3):480. PubMed ID: 32326913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
    Ward JW; Hinman AR
    Gastroenterology; 2019 Jan; 156(2):297-310. PubMed ID: 30391470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study.
    Trickey A; Fraser H; Lim AG; Walker JG; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Martin NK; Degenhardt L; Hickman M; May MT; Vickerman P
    J Viral Hepat; 2019 Dec; 26(12):1388-1403. PubMed ID: 31392812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
    Chikovani I; Ompad DC; Uchaneishvili M; Sulaberidze L; Sikharulidze K; Hagan H; Van Devanter NL
    PLoS One; 2019; 14(4):e0216123. PubMed ID: 31034530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress.
    Blach S; Brown KA; Brown RS; Gholam PM; Terrault NA; Estes C; Razavi HA
    J Infect Public Health; 2023 Jan; 16(1):64-70. PubMed ID: 36473359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.